Ovid Therapeutics (OVID) Insider Trading & Ownership $1.02 +0.01 (+0.99%) (As of 12/19/2024 05:49 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Ovid Therapeutics (NASDAQ:OVID) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage13.30%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$50,364.48Number OfInsiders Selling(Last 12 Months)0 Get OVID Insider Trade Alerts Want to know when executives and insiders are buying or selling Ovid Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address OVID Insider Buying and Selling by Quarter Ad Banyan Hill Publishing“Energy’s holy grail” just discoveredIt’s 17,000 times more powerful than gas… 2.75 million times more powerful than coal… and a staggering… 3 million times more powerful than oil. It could also save the United States as much as $2.2 trillion every year in energy costs. It’s no wonder this incredible new energy source is a major Trump priority. Find out what it is here. Ovid Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/18/2024Jeremy M LevinCEOBuy18,248$2.76$50,364.48 (Data available from 1/1/2013 forward) OVID Insider Trading Activity - Frequently Asked Questions Who is on Ovid Therapeutics's Insider Roster? The list of insiders at Ovid Therapeutics includes Jason Tardio, and Jeremy M Levin. Learn more on insiders at OVID. What percentage of Ovid Therapeutics stock is owned by insiders? 13.30% of Ovid Therapeutics stock is owned by insiders. Learn more on OVID's insider holdings. Which Ovid Therapeutics insiders have been buying company stock? The following insider purchased OVID shares in the last 24 months: Jeremy M Levin ($50,364.48). How much insider buying is happening at Ovid Therapeutics? Insiders have purchased a total of 18,248 OVID shares in the last 24 months for a total of $50,364.48 bought. Ovid Therapeutics Key ExecutivesDr. Jeremy Max Levin Ba Zoology (Age 71)Dphil, Mb Bchir, President, CEO & Chairman Compensation: $1.03MMr. Jeffrey A. Rona (Age 56)Chief Business and Financial Officer Compensation: $761.24kMr. Thomas Michael Perone J.D. (Age 59)M.B.A., General Counsel, Chief Compliance Officer & Corporate Secretary Compensation: $745.71kMr. Jason Tardio M.B.A. (Age 47)Chief Operating Officer Compensation: $652.84kMr. Simon D. Kelner (Age 50)Chief Human Resources Officer Dr. Dirk Haasner (Age 59)Senior Vice President of Global Manufacturing & CMC QA Compensation: $416.95kDr. Todd F. Baumgartner M.D.M.P.H., Senior Vice President of Regulatory AffairsDr. Julia Tsai Ph.D. (Age 49)Senior Vice President of Clinical Development Ms. Meg AlexanderChief Strategy OfficerDr. Manoj Malhotra M.D.Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies LRMR Insider Selling CMPS Insider Selling BNTC Insider Selling AMLX Insider Selling LFCR Insider Selling ITOS Insider Selling FHTX Insider Selling ELDN Insider Selling URGN Insider Selling RZLT Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:OVID) was last updated on 12/20/2024 by MarketBeat.com Staff From Our PartnersBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredBitcoin is going to $100,000 … before Inauguration DayMark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored 5 military stocks to invest in If you’re a person of action, you can get in on a new US superweapon so savage it dwarfs the atomic bomb. Spec...Paradigm Press | Sponsored‘Invisible’ AI stock is Wall Street legend’s top pick for 2025Chaikin spent decades working alongside famous investors Paul Tudor Jones, Michael Steinhardt, Steve Cohen, an...Chaikin Analytics | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.